Breast Cancer Screening Controversy: Too Much or Not Enough?
Overview
Authors
Affiliations
The Cochrane analysis exploring the risk/benefit ratio of breast cancer screening resulted in a controversy worldwide spread by the mass media. Our survey sought to assess the impact of this controversy in terms of breast cancer screening awareness and attendance. A nationwide observational study, recorded in the EDIFICE iterative surveys, with a representative sample of 451 women aged 40-75 years, living in France, was carried out in the 3 months after the start of the controversy in January 2013. Of the 405 women with no personal history of cancer, 69 (17%) declared having heard of the controversy (aware group). Women remembering the controversy were more likely to belong to higher socioprofessional categories and to have a higher level of education. The most frequently remembered issues were overdiagnosis (38%), unreliability (16%) and radiation risk (9%). Compared with women who were unaware of the controversy, the aware group knew more about the limits of breast cancer screening (undiagnosed cancers, 20 vs. 7%, P<0.05 and risk of false positives, 20 vs. 2%, P<0.05) and were more likely to change their opinion for the worse over the mass media debate (8.7 vs. 1.2%, P<0.05). Nevertheless, only 1% of the aware-group declared their intention to subsequently undergo screening less frequently. The low impact of the controversy on the behaviour of women with respect to screening suggests that it should not be seen as a threat to screening attendance rates, but more as an opportunity to improve awareness.
Villain P, Downham L, Le Bonniec A, Bauquier C, Mandrik O, Nadarzynski T J Med Internet Res. 2025; 27:e65974.
PMID: 39879616 PMC: 11822326. DOI: 10.2196/65974.
Guigon L, Sanchez L, Petit A, Le Bonniec A, Basu P, Rodrigue C BMC Public Health. 2024; 24(1):404.
PMID: 38326802 PMC: 10851553. DOI: 10.1186/s12889-024-17876-5.
Flemban A J Pers Med. 2023; 13(3).
PMID: 36983705 PMC: 10051653. DOI: 10.3390/jpm13030523.
Screening High-Risk Women Veterans for Breast Cancer.
Anna Park Y, Keller A, Hsu T, Bidassie B, Venne V, Hawley D Fed Pract. 2021; 38(Suppl 2):S35-S41.
PMID: 34177240 PMC: 8223736. DOI: 10.12788/fp.0122.
Viguier J, Morere J, Pivot X, Touboul C, Lhomel C, Couraud S Curr Oncol Rep. 2018; 20(Suppl 1):14.
PMID: 29508088 DOI: 10.1007/s11912-017-0646-x.